Bhakare Meenakshi, Nikalje Rajkumar, Patil Reshma, Shukla Urvi, Bokade Rupesh, Sakhare Gajanan, Joshi Shardul, Pais Aditi
Department of Respiratory Medicine, Symbiosis Medical College for Women and Symbiosis University Hospital and Research Centre, Symbiosis International (Deemed University), Pune, Maharashtra, India.
Symbiosis University Hospital and Research Centre, Symbiosis International (Deemed University), Pune, Maharashtra, India.
J Family Med Prim Care. 2023 Dec;12(12):3160-3166. doi: 10.4103/jfmpc.jfmpc_221_23. Epub 2023 Dec 21.
Understanding pulmonary function at various phases after coronavirus disease 2019 (COVID-19) infection is critical for determining the exact pathophysiological mechanism of COVID-19.
What is the correlation between spirometry indices and clinical indicators in COVID-19 patients over a 6-week follow-up?
A prospective observational study was conducted for a 6-week period among 25, COVID-19 patients who were either asymptomatic or mildly symptomatic. Each patient received a home-use-connected spirometer-SpiroPRO, a pulse oximeter, and a thermometer from Briota Technologies Pvt Ltd. (BRIOTA). Patients and healthcare professionals were given training for performing spirometry twice a day as well as access to mobile apps was provided. Spirometry indices, patient symptoms, and vital statistics were used to calculate the VIEW™ score using machine learning algorithms.
The Bland-Altman plots showed that FEV reduced slightly up to 21-28 days and comes back to normal around 42 days. VIEW™ score increased up to and then decreased toward . An increase in VIEW™ score increases the risk of COVID-19 complications. VIEW™ score and FEV showed a significant correlation.
Home-based spirometry acts as an effective tool for COVID-19 patients to predict lung complications and also promote self-monitoring thereby reducing the burden on the health system.
了解2019冠状病毒病(COVID-19)感染后不同阶段的肺功能对于确定COVID-19的确切病理生理机制至关重要。
在6周的随访中,COVID-19患者的肺量计指标与临床指标之间有何相关性?
1)评估COVID-19患者肺量计参数的恶化或改善情况,包括用力肺活量(FVC)、一秒用力呼气量(FEV)和FEV/FVC比值。2)研究FVC、FEV和FEV/FVC与血氧饱和度及临床发现之间的相关性。
对25例无症状或症状轻微的COVID-19患者进行了为期6周的前瞻性观察研究。每位患者均收到了Briota Technologies Pvt Ltd.(BRIOTA)提供的家用连接式肺量计SpiroPRO、脉搏血氧仪和温度计。患者和医护人员接受了每天两次进行肺量计检查的培训,并获得了移动应用程序的使用权限。使用机器学习算法,通过肺量计指标、患者症状和生命统计数据来计算VIEW™评分。
布兰德-奥特曼图显示,FEV在21至28天内略有下降,约42天时恢复正常。VIEW™评分先升高,然后下降。VIEW™评分升高会增加COVID-19并发症的风险。VIEW™评分与FEV显示出显著相关性。
家庭肺量计检查是COVID-19患者预测肺部并发症以及促进自我监测的有效工具,从而减轻卫生系统的负担。